Precision BioSciences reports cccDNA reduction in HBV study, activates second DMD site; updates deck
Precision BioSciences announced PBGENE-HBV data showing a 1-log reduction in cccDNA-derived transcripts and activation of a second FUNCTION-DMD clinical site.Key Highlights:Original SEC Filing: PRECISION BIOSCIENCES INC [ DTIL ] - 8-K - Jul. 01, 2026This is an AI-powered summary. It may contain ina…